SEC Form 10-Q filed by AptarGroup Inc.

William Blair downgraded AptarGroup from Outperform to Mkt Perform

KeyBanc Capital Markets initiated coverage of AptarGroup with a rating of Overweight and set a new price target of $220.00

Raymond James initiated coverage of AptarGroup with a rating of Outperform and set a new price target of $200.00

3 - APTARGROUP, INC. (0000896622) (Issuer)

4 - APTARGROUP, INC. (0000896622) (Issuer)

4 - APTARGROUP, INC. (0000896622) (Issuer)

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, today announced its participation at the Jefferies Global Healthcare Conference on Wednesday, November 19, 2025. Stephan Tanda, President and CEO, will present at 7:00 a.m. Eastern Standard Time. Vanessa Kanu, Executive Vice President and CFO, and Gael Touya, President Aptar Pharma, will also be available. A live audio webcast and presentation materials will be available in the "Investors" section of the Company's website at www.aptar.com. About Aptar Aptar is a global leader in drug delivery and consumer product dosing, dispensing and protection technol

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, today reported the following third quarter results for the period ended September 30, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030956269/en/Aptar Reports Third Quarter 2025 Results Third Quarter 2025 Highlights (Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 6% and core sales increased 1% Strong product volume growth

Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, today announced that the U.S Food and Drug Administration (FDA) has granted 510(k) clearance for HeroTracker® Sense as a Class II medical device. This milestone recognizes HeroTracker® Sense - a Bluetooth-enabled sensor - as an innovative connected add-on for pressurized Metered Dose Inhalers (pMDIs), transforming traditional inhalers into smart, data-driven devices for patients and healthcare professionals. Designed for individuals aged 12 and above, HeroTracker® Sense is compatible with several commonly prescribed asthma and chronic obstructive pulmonary disease (COPD) medications, includ

8-K - APTARGROUP, INC. (0000896622) (Filer)

424B5 - APTARGROUP, INC. (0000896622) (Filer)

FWP - APTARGROUP, INC. (0000896622) (Subject)

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dosing, dispensing and protection technologies, today reported the following third quarter results for the period ended September 30, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251030956269/en/Aptar Reports Third Quarter 2025 Results Third Quarter 2025 Highlights (Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures) Reported sales increased 6% and core sales increased 1% Strong product volume growth

Following an increase of almost 10% a year ago AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.48 per share, an almost 7% increase from the previous dividend amount, bringing the new annualized dividend to $1.92 per share. The payment date is November 13, 2025, to stockholders of record as of October 23, 2025. Stephan B. Tanda, Aptar President and CEO, commented, "Given the strength of our business outlook, the sustained long-term growth we anticipate from our Pharma segment, and our continued strong performance across all key financial metrics, the Board of Dir

AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported the following second quarter results for the period ended June 30, 2025, as compared to the corresponding period of the last fiscal year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250731446602/en/Aptar Reports Second Quarter 2025 Results Second Quarter 2025 Highlights (compared to the prior year quarter) Reported sales increased 6% and core sales increased 3% Reported net income increased 24% to $112 million and adjusted EBITDA increased 13% from the prior year to $218 million Rep

Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,

AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905451175/en/Sarah Glickman Joins Aptar's Board of Directors (Photo: Aptar) "We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah's extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005172/en/Julie Xing Joins Aptar's Board of Directors (Photo: Aptar) With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie's leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple g

SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)

SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)

SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)